National Pension Service boosted its position in Pfizer Inc. (NYSE:PFE) by 2.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,638,217 shares of the biopharmaceutical company’s stock after buying an additional 104,546 shares during the quarter. Pfizer makes up about 0.8% of National Pension Service’s portfolio, making the stock its 23rd biggest position. National Pension Service owned about 0.08% of Pfizer worth $167,996,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in the stock. Vanguard Group Inc. raised its position in Pfizer by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock valued at $14,062,088,000 after buying an additional 9,239,499 shares during the last quarter. Ameriprise Financial Inc. increased its position in shares of Pfizer by 4.4% during the 3rd quarter. Ameriprise Financial Inc. now owns 59,844,024 shares of the biopharmaceutical company’s stock worth $2,136,189,000 after purchasing an additional 2,502,659 shares during the last quarter. Franklin Resources Inc. increased its position in shares of Pfizer by 0.9% during the 2nd quarter. Franklin Resources Inc. now owns 46,167,213 shares of the biopharmaceutical company’s stock worth $1,550,754,000 after purchasing an additional 389,629 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Pfizer by 4.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 44,286,544 shares of the biopharmaceutical company’s stock worth $1,487,617,000 after purchasing an additional 2,028,313 shares during the last quarter. Finally, Fisher Asset Management LLC increased its position in shares of Pfizer by 3.2% during the 3rd quarter. Fisher Asset Management LLC now owns 35,120,799 shares of the biopharmaceutical company’s stock worth $1,253,813,000 after purchasing an additional 1,085,437 shares during the last quarter. 71.41% of the stock is currently owned by institutional investors and hedge funds.
Several research analysts have weighed in on the company. BMO Capital Markets set a $43.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Tuesday, March 6th. Berenberg Bank set a $36.00 price target on Pfizer and gave the stock a “neutral” rating in a research report on Tuesday, January 30th. Jefferies Group set a $39.00 price target on Pfizer and gave the stock a “hold” rating in a research report on Monday, February 26th. UBS Group set a $42.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Wednesday, January 31st. Finally, Leerink Swann boosted their price target on Pfizer from $35.00 to $38.00 and gave the stock a “market perform” rating in a research report on Wednesday, January 31st. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $39.40.
In related news, Director W Don Cornwell sold 1,758 shares of the business’s stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $36.79, for a total value of $64,676.82. Following the completion of the sale, the director now directly owns 1,000 shares in the company, valued at approximately $36,790. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Kirsten Lund-Jurgensen sold 9,510 shares of the business’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $37.19, for a total value of $353,676.90. Following the completion of the sale, the insider now owns 36,959 shares of the company’s stock, valued at $1,374,505.21. The disclosure for this sale can be found here. Insiders sold a total of 248,037 shares of company stock valued at $9,064,785 over the last 90 days. 0.06% of the stock is currently owned by corporate insiders.
Shares of Pfizer Inc. (NYSE:PFE) opened at $36.58 on Friday. The stock has a market capitalization of $217,760.00, a price-to-earnings ratio of 20.90, a P/E/G ratio of 2.07 and a beta of 0.91. Pfizer Inc. has a one year low of $31.67 and a one year high of $39.43. The company has a quick ratio of 1.10, a current ratio of 1.35 and a debt-to-equity ratio of 0.47.
Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.56 by $0.06. The business had revenue of $13.70 billion during the quarter, compared to the consensus estimate of $13.67 billion. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. The firm’s quarterly revenue was up .6% on a year-over-year basis. During the same period in the previous year, the company posted $0.47 EPS. equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Thursday, March 1st. Investors of record on Friday, February 2nd were paid a $0.34 dividend. The ex-dividend date was Thursday, February 1st. This is an increase from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 annualized dividend and a yield of 3.72%. Pfizer’s payout ratio is 77.71%.
Pfizer announced that its board has initiated a stock buyback plan on Monday, December 18th that permits the company to repurchase $10.00 billion in shares. This repurchase authorization permits the biopharmaceutical company to purchase shares of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board of directors believes its stock is undervalued.
COPYRIGHT VIOLATION NOTICE: “Pfizer Inc. (PFE) Stake Boosted by National Pension Service” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.dispatchtribunal.com/2018/03/16/pfizer-inc-pfe-stake-boosted-by-national-pension-service.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.